Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.69 |
| ▸ | NPC1 | O15118 | 9/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.69 |
| ▸ | PIM1 | P11309 | 1/20 | 0.69 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.69 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.69 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.69 |
| ▸ | FLT3 | P36888 | 1/20 | 0.69 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.69 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 5/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17079611 | 0.85 | GRM4 (0.67) | RAB9ANPC1SMN1; SMN2ADORA3PIM1 | |
| SCHEMBL27600377 | 0.83 | MAPT (0.61) | RAB9ASMN1; SMN2LMNAALDH1A1MEN1 | |
| SCHEMBL9317689 | 0.82 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2ADORA3PIM1 | |
| SCHEMBL11056656 | 0.81 | MAPT (0.75) | RAB9ANPC1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL11054945 | 0.80 | MAPT (0.81) | RAB9ASMN1; SMN2LMNAALDH1A1MEN1 | |
| SCHEMBL9750118 | 0.80 | NPC1 (0.81) | RAB9ANPC1SMN1; SMN2ADORA3PIM1 | |
| SCHEMBL30418675 | 0.80 | RAB9A (0.77) | RAB9ANPC1SMN1; SMN2ADORA3PIM1 | |
| SCHEMBL5851699 | 0.80 | RAB9A (0.77) | RAB9ANPC1SMN1; SMN2ADORA3PIM1 | |
| SCHEMBL14324763 | 0.80 | NPC1 (0.76) | RAB9ANPC1SMN1; SMN2ADORA3PIM1 | |
| SCHEMBL1530634 | 0.79 | GRM4 (0.72) | RAB9ANPC1SMN1; SMN2MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015136292-A9 | USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS | UNIVERSITY OF WARWICK (GB) | 2022-04-21 | — | — | WO | disclosed |
| WO-2015136292-A9 | USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS | UNIVERSITY OF WARWICK (GB) | 2022-04-21 | — | — | WO | disclosed |
| US-9884812-B2 | Use of DDX3X inhibitors for the treatment of pneumovirus infections | UNIVERSITY OF WARWICK (GB) | 2018-02-06 | — | — | US | disclosed |
| US-9884812-B2 | Use of DDX3X inhibitors for the treatment of pneumovirus infections | UNIVERSITY OF WARWICK (GB) | 2018-02-06 | — | — | US | disclosed |
| US-20170166519-A1 | USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS | UNIVERSITY OF WARWICK (GB) | 2017-06-15 | — | — | US | disclosed |
| US-20170166519-A1 | USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS | UNIVERSITY OF WARWICK (GB) | 2017-06-15 | — | — | US | disclosed |
| EP-3116852-A1 | USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS | University of Warwick (GB) | 2017-01-18 | — | — | EP | disclosed |
| WO-2015136292-A1 | USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS | UNIVERSITY OF WARWICK (GB) | 2015-09-17 | — | — | WO | disclosed |
| WO-2015136292-A1 | USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS | UNIVERSITY OF WARWICK (GB) | 2015-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166519-A1 | USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS | DDX3X, DDX1, DDX5 | RAB9A 873/4885NPC1 2429/4885SMN1; SMN2 4187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.